
Release date: 2024-08-08 16:08:05 Article From: Lucius Laos Recommended: 263
Capmatinib is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC) in patients with mutations in the MET gene, particularly MET exon 14 skipping mutations.
Before using drugs for treatment, patients and doctors should pay attention to the precautions for the use of drugs, which are organized as follows according to the drug instructions:
In the GEOMETRY mono-1 study, 14 percent of patients experienced elevated levels of amylase and lipase after capmatinib, 7 percent experienced grade 3 elevations, and 1.9 percent experienced grade 4 elevations.
Regular monitoring of amylase and lipase before and during treatment is recommended, and consideration may be given to temporary, dose reduction, or permanent discontinuation depending on the severity of adverse effects.
Some patients have experienced severe allergic reactions to capmatinib with symptoms including fever, chills, itching, rash, drop in blood pressure, nausea, and vomiting. Depending on the severity of the adverse effects, temporary or permanent discontinuation may be required.
The most common adverse events during the treatment of capmatinib are some of the symptoms that patients generally experience, and these adverse reactions affect a significant proportion of patients (≥20% of patients reported).
Nausea is an unpleasant feeling of wanting to vomit, often accompanied by discomfort in the upper abdomen or a feeling of stomach upside down. It is one of the common side effects and can be caused by direct irritation of the mucosa of the gastrointestinal tract or by affecting the central nervous system.
Dyspnea is characterized by the patient having to breathe strained, requiring rapid breathing or repositioning for relief. This may be a drug allergy, impaired lung function, or an increased cardiovascular burden. If you have this symptom, you should seek medical attention promptly.
[Warm tips] The adverse reactions listed above do not occur in every patient, and the severity and duration of symptoms may also vary from person to person. During the treatment, patients should pay close attention to their physical reactions and report the discomfort symptoms to the doctor in a timely manner.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1532025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1712025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1872025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1672025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1622025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: